CLINICAL_TRIALS
trial_result
· 2020-02-10
Clinical Trial Update: A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS [Phase 2]
Summary
Phase 2 pilot trial assessing rituximab for treatment-resistant focal segmental glomerulosclerosis has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Mayo Clinic | Conditions: Primary Focal Segmental Glomerulosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2020-02-10